Literature DB >> 26739213

DPP-4 inhibition has beneficial effects on the heart after myocardial infarction.

Akihiko Kubota1, Hiroyuki Takano2, Haixiu Wang3, Hiroshi Hasegawa1, Hiroyuki Tadokoro4, Masanori Hirose1, Yuka Kobara1, Tomoko Yamada-Inagawa3, Issei Komuro5, Yoshio Kobayashi1.   

Abstract

AIMS: Dipeptidyl peptidase-4 (DPP-4) inhibitors are reported to have protective effects on various cells but it is unclear how DPP-4 inhibitors have cardioprotective effects. Our aim was to study the mechanisms of cardioprotective effects by DPP-4 inhibition. METHODS AND
RESULTS: C57BL/6 mice and DPP-4 knockout (DPP-4KO) mice were subjected to left coronary artery ligation to produce acute myocardial infarction (MI). C57BL/6 mice were then treated with vehicle or DPP-4 inhibitor. Left ventricular function, infarct size, the number of vessels, and myocardial ischemia were assessed at 5days after MI. The treatment with DPP-4 inhibitor significantly improved cardiac function and decreased the infarct size. DPP-4 inhibitor increased the ratio of endothelial cell numbers to a cardiomyocyte. The extent of myocardial ischemia and the number of TUNEL-positive cells in the border area were significantly decreased by DPP-4 inhibitor. Stromal cell-derived factor-1α (SDF-1α) level in myocardium was significantly increased by DPP-4 inhibitor. Those cardioprotective effects after MI were also recognized in DPP-4KO mice. DPP-4 protein was expressed on rat neonatal cardiomyocytes and DPP-4 inhibitor significantly reduced hypoxia-induced apoptosis in the cardiomyocytes. However, this effect was abolished by the pretreatment with a CXCR4 antagonist or a signal transducer and activator of transcription 3 (STAT3) inhibitor. The beneficial effects of DPP-4 inhibitor on heart failure after MI were abolished by cardiomyocyte-specific deletion of STAT3.
CONCLUSIONS: DPP-4 inhibition may have direct protective effects on the post-MI heart by inducing an antiapoptotic effect and inhibiting a decrease in vessel number through the SDF-1α/CXCR4-mediated STAT3 signaling pathway.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; DPP-4; Heart failure; Myocardial infarction; STAT3

Mesh:

Substances:

Year:  2015        PMID: 26739213     DOI: 10.1016/j.yjmcc.2015.12.026

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  13 in total

Review 1.  Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.

Authors:  Bárbara Torrecillas-Baena; María Ángeles Gálvez-Moreno; José Manuel Quesada-Gómez; Gabriel Dorado; Antonio Casado-Díaz
Journal:  Stem Cell Rev Rep       Date:  2021-10-22       Impact factor: 5.739

Review 2.  Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials.

Authors:  John R Ussher; Amanda A Greenwell; My-Anh Nguyen; Erin E Mulvihill
Journal:  Diabetes       Date:  2022-02-01       Impact factor: 9.461

3.  The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.

Authors:  Mei-Tzu Wang; Sheng-Che Lin; Pei-Ling Tang; Wang-Ting Hung; Chin-Chang Cheng; Jin-Shiou Yang; Hong-Tai Chang; Chun-Peng Liu; Guang-Yuan Mar; Wei-Chun Huang
Journal:  Cardiovasc Diabetol       Date:  2017-07-11       Impact factor: 9.951

Review 4.  Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.

Authors:  Milton Packer
Journal:  Cardiovasc Diabetol       Date:  2018-01-08       Impact factor: 9.951

Review 5.  The regulatory role of DPP4 in atherosclerotic disease.

Authors:  Lihua Duan; Xiaoquan Rao; Chang Xia; Sanjay Rajagopalan; Jixin Zhong
Journal:  Cardiovasc Diabetol       Date:  2017-06-15       Impact factor: 9.951

6.  Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor.

Authors:  Yusuke Takahara; Tomotake Tokunou; Toshihiro Ichiki
Journal:  J Atheroscler Thromb       Date:  2018-01-10       Impact factor: 4.928

Review 7.  Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection.

Authors:  Marina Rankovic; Nevena Jeremic; Ivan Srejovic; Katarina Radonjic; Aleksandra Stojanovic; Milos Glisic; Stefani Bolevich; Sergey Bolevich; Vladimir Jakovljevic
Journal:  Heart Fail Rev       Date:  2021-03       Impact factor: 4.214

8.  Role of SDF-1:CXCR4 in Impaired Post-Myocardial Infarction Cardiac Repair in Diabetes.

Authors:  Maritza E Mayorga; Matthew Kiedrowski; Patricia McCallinhart; Farhad Forudi; Jeremiah Ockunzzi; Kristal Weber; William Chilian; Marc S Penn; Feng Dong
Journal:  Stem Cells Transl Med       Date:  2017-11-09       Impact factor: 6.940

9.  The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.

Authors:  Fausto Chiazza; Harald Tammen; Hiranya Pintana; Grazyna Lietzau; Massimo Collino; Thomas Nyström; Thomas Klein; Vladimer Darsalia; Cesare Patrone
Journal:  Cardiovasc Diabetol       Date:  2018-05-19       Impact factor: 9.951

10.  Saxagliptin Attenuates Albuminuria by Inhibiting Podocyte Epithelial- to-Mesenchymal Transition via SDF-1α in Diabetic Nephropathy.

Authors:  Yun-Peng Chang; Bei Sun; Zhe Han; Fei Han; Shao-Lan Hu; Xiao-Yu Li; Mei Xue; Yang Yang; Li Chen; Chun-Jun Li; Li-Ming Chen
Journal:  Front Pharmacol       Date:  2017-11-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.